Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
71.4M
-
Number of holders
-
112
-
Total 13F shares, excl. options
-
55.4M
-
Shares change
-
+1.18M
-
Total reported value, excl. options
-
$588M
-
Value change
-
+$13.7M
-
Put/Call ratio
-
1.78
-
Number of buys
-
49
-
Number of sells
-
-49
-
Price
-
$10.62
Significant Holders of Phathom Pharmaceuticals, Inc. - Common Stock (PHAT) as of Q1 2024
132 filings reported holding PHAT - Phathom Pharmaceuticals, Inc. - Common Stock as of Q1 2024.
Phathom Pharmaceuticals, Inc. - Common Stock (PHAT) has 112 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 55.4M shares
of 71.4M outstanding shares and own 77.6% of the company stock.
Largest 10 shareholders include Frazier Life Sciences Management, L.P. (10.1M shares), Medicxi Ventures Management (Jersey) Ltd (7.46M shares), Carlyle Group Inc. (3.5M shares), Invesco Ltd. (3.16M shares), TAKEDA PHARMACEUTICAL CO LTD (3.15M shares), BlackRock Inc. (2.75M shares), Ensign Peak Advisors, Inc (2.28M shares), VANGUARD GROUP INC (1.98M shares), NEA Management Company, LLC (1.96M shares), and Avidity Partners Management LP (1.74M shares).
This table shows the top 112 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.